---
title: "Key facts: AstraZeneca (AZN) talks stall; €2.55bn bond, $198 PT"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296872454.md"
description: "AstraZeneca's merger talks with Bristol Myers Squibb have stalled due to opposition, making a deal unlikely under current terms. Additionally, AstraZeneca issued €2.55bn in Eurobonds maturing between 2030 and 2038. Meanwhile, CICC published a price target of $198 per share for AstraZeneca."
datetime: "2026-08-25T07:14:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296872454.md)
  - [en](https://longbridge.com/en/news/296872454.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296872454.md)
generator: "portal-rs"
---

# Key facts: AstraZeneca (AZN) talks stall; €2.55bn bond, $198 PT

-   AstraZeneca (AZN) held merger talks with U.S. peer Bristol Myers Squibb; sources say talks faced opposition and a deal is unlikely to move forward under current terms. Reuters
-   AstraZeneca (AZN) issued €2.55bn Eurobond via AstraZeneca Finance: four fixed‑rate tranches maturing 2030–2038 with coupons 3.402%–4.169%, LSE‑listed, guaranteed by AstraZeneca, closing 1 Sep 2026 2 sources
-   CICC published a price target of $198.00 per share for AstraZeneca PLC (AZN); the note specifies that this valuation applies to AstraZeneca PLC (AZN) shares and sets the target at $198.00 per share. Dow Jones Newswires

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [03908.HK](https://longbridge.com/en/quote/03908.HK.md)
- [601995.CN](https://longbridge.com/en/quote/601995.CN.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Bristol Myers presents results for EXPLORER-LTE cohort of MAVA-LTE study](https://longbridge.com/en/news/297453992.md)
- [REG - AstraZeneca PLC - AstraZeneca completes agreement for Zegfrovy](https://longbridge.com/en/news/297603898.md)
- [Key facts: LSE:AZN Zegfrovy buy; SANOVO PFS; Wan Ling Martello named](https://longbridge.com/en/news/297611733.md)
- [AstraZeneca Reports Positive Results Of SANOVO Phase III Trial In China](https://longbridge.com/en/news/297606938.md)
- [AstraZeneca Shares Dual Oncology Clinical and Regulatory Victories](https://longbridge.com/en/news/297649754.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**